Gossamer Bio Inc (NASDAQ:GOSS) — Market Cap & Net Worth
Market Cap & Net Worth: Gossamer Bio Inc (GOSS)
Gossamer Bio Inc (NASDAQ:GOSS) has a market capitalization of $85.64 Million ($85.64 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19769 globally and #4294 in its home market, demonstrating a -0.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gossamer Bio Inc's stock price $0.37 by its total outstanding shares 231456247 (231.46 Million). Analyse Gossamer Bio Inc (GOSS) cash flow conversion to see how efficiently the company converts income to cash.
Gossamer Bio Inc Market Cap History: 2019 to 2026
Gossamer Bio Inc's market capitalization history from 2019 to 2026. Data shows change from $3.62 Billion to $85.64 Million (-41.54% CAGR).
Index Memberships
Gossamer Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #563 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1917 of 3165 |
Weight: Gossamer Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gossamer Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gossamer Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.83x
Gossamer Bio Inc's market cap is 1.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $209.38 Million | $114.70 Million | -$56.53 Million | 1.83x | N/A |
Competitor Companies of GOSS by Market Capitalization
Companies near Gossamer Bio Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Gossamer Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Gossamer Bio Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Gossamer Bio Inc's market cap moved from $3.62 Billion to $ 85.64 Million, with a yearly change of -41.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $85.64 Million | -88.06% |
| 2025 | $717.51 Million | +242.69% |
| 2024 | $209.38 Million | -0.92% |
| 2023 | $211.32 Million | -57.93% |
| 2022 | $502.26 Million | -80.81% |
| 2021 | $2.62 Billion | +16.96% |
| 2020 | $2.24 Billion | -38.13% |
| 2019 | $3.62 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Gossamer Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.64 Million USD |
| MoneyControl | $85.64 Million USD |
| MarketWatch | $85.64 Million USD |
| marketcap.company | $85.64 Million USD |
| Reuters | $85.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more